Hemispherx BioPharma Stock Forecast, Price & News

Wall Street analysts have given Hemispherx BioPharma a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Hemispherx BioPharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) released its earnings results on Thursday, August, 15th. The specialty pharmaceutical company reported ($1.07) earnings per share for the quarter, topping the consensus estimate of ($1.70) by $0.63. The specialty pharmaceutical company earned $0.03 million during the quarter.
View Hemispherx BioPharma's earnings history.

Hemispherx BioPharma shares reverse split before market open on Tuesday, June 11th 2019. The 1-44 reverse split was announced on Friday, May 31st 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 10th 2019. An investor that had 100 shares of Hemispherx BioPharma stock prior to the reverse split would have 2 shares after the split.

Some companies that are related to Hemispherx BioPharma include ImmuPharma (IMM), AorTech International (AOR), iCo Therapeutics (ICO), Kane Biotech (KNE), Hemogenyx Pharmaceuticals (HEMO), Biopharmx (BPMX), Crescita Therapeutics (CTX), Hvivo (HVO), Quest PharmaTech (QPT), Realm Therapeutics (RLM), Hemostemix (HEM), ValiRx (VAL), Medicure (MPH), Naturally Splendid Enterprises (NSP) and Nuformix (NFX).
View all of HEB's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Hemispherx BioPharma investors own include NewLink Genetics (NLNK), Biocept (BIOC), (GDPMQ) (GDPMQ), Inovio Pharmaceuticals (INO), Palatin Technologies (PTN), Biopharmx (BPMX), CTI BioPharma (CTIC), Advaxis (ADXS), Cytori Therapeutics (CYTX) and Frontier Communications (FTR).

Hemispherx BioPharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "HEB."

Shares of HEB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HEB stock can currently be purchased for approximately $2.09.

Hemispherx BioPharma has a market capitalization of $5.10 million.

Hemispherx BioPharma employs 31 workers across the globe.

The official website for Hemispherx BioPharma is www.hemispherx.net.

Hemispherx BioPharma is headquartered at 860 N Orange Ave Ste B, ORLANDO, FL 32801-5205, United States.

Hemispherx BioPharma's mailing address is 860 N Orange Ave Ste B, ORLANDO, FL 32801-5205, United States. The specialty pharmaceutical company can be reached via phone at +1-407-2718516.